Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians
暂无分享,去创建一个
L. Calò | N. Girerd | G. Cice | I. Ferrari | C. Tota | L. Monzo | F. Cicogna
[1] Akshay S. Desai,et al. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial. , 2022, JAMA cardiology.
[2] L. Calò,et al. Sodium–glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome , 2022, European heart journal supplements : journal of the European Society of Cardiology.
[3] M. Landray,et al. Empagliflozin in Patients with Chronic Kidney Disease , 2022, The New England journal of medicine.
[4] Akshay S. Desai,et al. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction , 2022, JAMA cardiology.
[5] G. Filippatos,et al. Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure , 2022, JAMA cardiology.
[6] Akshay S. Desai,et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. , 2022, The New England journal of medicine.
[7] J. Ferreira,et al. Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance , 2022, ESC heart failure.
[8] Akshay S. Desai,et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials , 2022, The Lancet.
[9] Lin Qiu,et al. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis , 2022, Cardiovascular Diabetology.
[10] L. Calò,et al. What proportion of patients with heart failure and preserved ejection fraction are eligible for empagliflozin? , 2022, Journal of cardiovascular medicine.
[11] P. Schulze,et al. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF) , 2022, Circulation.
[12] M. Link,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.
[13] S. Pocock,et al. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled , 2022, European heart journal.
[14] G. Filippatos,et al. Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. , 2022, Journal of the American College of Cardiology.
[15] P. Ponikowski,et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial , 2022, Nature Medicine.
[16] G. Filippatos,et al. Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR‐Preserved trial , 2022, European journal of heart failure.
[17] G. Sinagra,et al. [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.
[18] H. Hillege,et al. A Systematic Review and Network-Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. , 2021, JACC. Heart failure.
[19] P. Ponikowski,et al. Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. , 2021, Journal of the American College of Cardiology.
[20] P. Ponikowski,et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.
[21] J. McMurray,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.
[22] L. Calò,et al. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction. , 2021, International journal of cardiology.
[23] P. Ponikowski,et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology , 2021, European journal of heart failure.
[24] P. Ponikowski,et al. Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial , 2021, European journal of heart failure.
[25] P. Ponikowski,et al. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. , 2021, JAMA cardiology.
[26] P. Ponikowski,et al. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. , 2021, JACC. Heart failure.
[27] G. Filippatos,et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial , 2021, European heart journal.
[28] Vinni Makin,et al. The role of SGLT-2 inhibitors in managing type 2 diabetes , 2020, Cleveland Clinic Journal of Medicine.
[29] F. Giorgino,et al. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk , 2020, Cardiovascular Diabetology.
[30] Deepak L. Bhatt,et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.
[31] G. Filippatos,et al. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction , 2020, Circulation.
[32] G. Filippatos,et al. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function , 2020, Circulation.
[33] J. McMurray,et al. Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.
[34] Akshay S. Desai,et al. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction , 2020, Circulation.
[35] P. Ponikowski,et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.
[36] G. Filippatos,et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.
[37] McKenzie Ferguson,et al. Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors , 2020, The Annals of pharmacotherapy.
[38] D. DeMets,et al. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF , 2020, Circulation.
[39] Akshay S. Desai,et al. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. , 2020, JACC. Heart failure.
[40] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[41] M. Vaduganathan,et al. Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists. , 2019, JACC. Heart failure.
[42] B. Vergès,et al. Adverse effects and safety of SGLT-2 inhibitors. , 2014, Diabetes & metabolism.
[43] Naoki Sato,et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. , 2014, Journal of the American College of Cardiology.
[44] K. Johnsson,et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. , 2013, Journal of diabetes and its complications.
[45] Hans L. Hillege,et al. Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure , 2006, Circulation.